(IN BRIEF) Sandoz has received European Commission approval for two biosimilar insulin products, Bysumlog® (insulin lispro) and Dazparda® (insulin aspart), for the treatment of diabetes mellitus across Europe. Developed by Gan & Lee Pharmaceuticals, the products are intended to improve … Read the full press release →
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged affordable medicines, Armin Metzger, biologic medicines, biosimilar market, biosimilar medicines, biosimilars, blood glucose management, Bysumlog, Bysumlog® and Dazparda® Approvals Mark Latest Expansion of Sandoz Diabetes Strategy, chronic disease, Dazparda, diabetes care, Diabetes Mellitus, diabetes prevalence, diabetes treatment, European Commission, European healthcare, Gan & Lee Pharmaceuticals, healthcare access, healthcare expenditure, Humalog, insulin analogues, insulin aspart, insulin lispro, insulin products, insulin therapy, NovoRapid, Ondibta, pharmaceutical approvals, pharmaceutical industry, Sandoz, Sandoz Strengthens Biosimilars Leadership Through New Diabetes Treatment Approvals
20-6-2013 — /europawire.eu/ — AstraZeneca and Bristol-Myers Squibb announced today top-line results of the Phase IV SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza ® (saxagliptin). In this study of adult patients with … Read the full press release →
Posted in Healthcare, Pharma & Biotech, Science, United Kingdom
Tagged anti-diabetic therapies, AstraZeneca, autoimmune, biopharmaceutical, biopharmaceutical business, Bristol-Myers Squibb, cardiovascular, cardiovascular death, cardiovascular disease, clinical trial, Diabetes Mellitus, Hadassah University Medical Center, infection, inflammation, metabolic, neuroscience diseases, non-fatal ischaemic stroke, non-fatal myocardial infarction, oncology, Onglyza, prescription medicines, respiratory, SAVOR-TIMI-53, saxagliptin, TIMI Study Group, type 2 diabetes
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?
Load more...
